Molecular targeted therapy for advanced gastric cancer
The Korean Journal of Internal Medicine
;
: 149-155, 2013.
Artigo
em Inglês
| WPRIM
| ID: wpr-117700
ABSTRACT
Although medical treatment has been shown to improve quality of life and prolong survival, no significant progress has been made in the treatment of advanced gastric cancer (AGC) within the last two decades. Thus, the optimum standard first-line chemotherapy regimen for AGC remains debatable, and most responses to chemotherapy are partial and of short duration; the median survival is approximately 7 to 11 months, and survival at 2 years is exceptionally > 10%. Recently, remarkable progress in tumor biology has led to the development of new agents that target critical aspects of oncogenic pathways. For AGC, many molecular targeting agents have been evaluated in international randomized studies, and trastuzumab, an anti-HER-2 monoclonal antibody, has shown antitumor activity against HER-2-positive AGC. However, this benefit is limited to only ~20% of patients with AGC (patients with HER-2-positive AGC). Therefore, there remains a critical need for both the development of more effective agents and the identification of molecular predictive and prognostic markers to select those patients who will benefit most from specific chemotherapeutic regimens and targeted therapies.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Gástricas
/
Transdução de Sinais
/
Resultado do Tratamento
/
Receptor ErbB-2
/
Inibidores da Angiogênese
/
Inibidores de Proteínas Quinases
/
Terapia de Alvo Molecular
/
Receptores ErbB
/
Antineoplásicos
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo prognóstico
Limite:
Animais
/
Humanos
Idioma:
Inglês
Revista:
The Korean Journal of Internal Medicine
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS